Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Through this partnership, UNLEASH and The Josh Bersin Company will introduce exclusive AI-focused workshops, featuring live ...

Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.